Description: Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests. Further, the company offers fungal pathogen analyte specific reagents; human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Additionally, the company provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. Applied BioCode Corporation is based in Santa Fe Springs, California.
Home Page: www.apbiocode.com
12130 Mora Dr.
Santa Fe Springs,
CA
90670
United States
Phone:
833 246 2633
Officers
| Name | Title |
|---|---|
| Mr. Christopher M. Bernard | Chief Exec. Officer |
| Dr. Winston Z. Ho Ph.D. | Founder, Pres, CTO & Director |
| Mr. Jaca Liang-Kai Huang | Chief Financial Officer |
| Mr. Gerald Kowalski | VP of Operations |
| Ms. Jau-Tung Pan | Accounting Supervisor |
| Dr. Michael Aye Ph.D. | Chief Scientific Officer |
| Yu-Tsung Chou | Chief Information Officer |
| Ms. Parisa Hanachi Ph.D. | Marketing Director |
| Craig Griz Adams | Sales Director |
| Julian Sanchez | Director of HR |
Exchange: TW
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9455 |
| Price-to-Sales TTM: | 6.7832 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |